Orthos Europe has been acquired by Atrium Innovations
Holland Venture has sold Orthos Europe to Atrium Innovations.
Orthos Europe’s main brand is AOV under which high-quality food supplements such as multi-vitamins, minerals, probiotics, enzymes, fatty acids and antioxidants are developed and marketed. The company was founded over 20 years ago and has a very strong position in the Netherlands, where it is a leading player in its market segment.
Atrium Innovations is a developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. Atrium markets a portfolio of finished products through its sales and marketing network in more than 35 countries, primarily in North America and Europe.
Holland Venture is an independent private equity fund located in Amsterdam. Since 1981, Holland Venture has realized the growth potential of many of its investments and has proven to be a trustworthy partner.
Oaklins' team in the Netherlands advised the seller in this transaction.
Contacter l'équipe de la transaction
Maarten Wolleswinkel
Oaklins Netherlands
Transactions connexes
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
En apprendre plusRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
En apprendre plusLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
En apprendre plus